- Home
- JGH vs CRMD Comparison
JGH vs CRMD Comparison
Compare JGH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- CRMD
- Stock Information
- Founded
- JGH 2014
- CRMD 2006
- Country
- JGH United States
- CRMD United States
- Employees
- JGH N/A
- CRMD N/A
- Industry
- JGH Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- CRMD Health Care
- Exchange
- JGH Nasdaq
- CRMD Nasdaq
- Market Cap
- JGH 304.1M
- CRMD 279.7M
- IPO Year
- JGH N/A
- CRMD 2010
- Fundamental
- Price
- JGH $12.97
- CRMD $12.04
- Analyst Decision
- JGH
- CRMD Strong Buy
- Analyst Count
- JGH 0
- CRMD 5
- Target Price
- JGH N/A
- CRMD $13.60
- AVG Volume (30 Days)
- JGH 73.9K
- CRMD 909.2K
- Earning Date
- JGH 01-01-0001
- CRMD 11-12-2024
- Dividend Yield
- JGH 9.85%
- CRMD N/A
- EPS Growth
- JGH N/A
- CRMD N/A
- EPS
- JGH N/A
- CRMD N/A
- Revenue
- JGH N/A
- CRMD $806,119.00
- Revenue This Year
- JGH N/A
- CRMD N/A
- Revenue Next Year
- JGH N/A
- CRMD $206.77
- P/E Ratio
- JGH N/A
- CRMD N/A
- Revenue Growth
- JGH N/A
- CRMD 2107.40
- 52 Week Low
- JGH $10.36
- CRMD $2.57
- 52 Week High
- JGH $12.85
- CRMD $12.07
- Technical
- Relative Strength Index (RSI)
- JGH 38.66
- CRMD 90.23
- Support Level
- JGH $12.99
- CRMD $9.67
- Resistance Level
- JGH $13.15
- CRMD $10.66
- Average True Range (ATR)
- JGH 0.11
- CRMD 0.51
- MACD
- JGH -0.05
- CRMD 0.14
- Stochastic Oscillator
- JGH 13.73
- CRMD 98.48
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.